Affimed Reports Third Quarter 2022 Financial Results

AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need...

Related Keywords

Germany ,Heidelberg ,Baden Wüberg ,United States ,Mannheim ,Texas ,American ,Adi Hoess ,Artiva Biotherapeutics ,Yago Nieto ,International Financial Reporting Standards ,University Of Texas Md Anderson Cancer Center ,Genentech ,Society For Immunotherapy Of Cancer ,Drug Administration ,International Accounting Standard Board ,American Society Of Hematology ,Clinical Stage Program Updates ,Department Of Hematology ,Heidelberg University ,Investigational New Drug ,Stem Cell Transplantation ,Cellular Therapy ,Cancer Center ,American Society ,Annual Meeting ,Medical Faculty Mannheim ,Nasdaq Afmd ,Affimednv ,